A century-old pill costing just $4 a month slashes insulin needs by 12% in type 1 diabetes patients, defying medical expectations and challenging billion-dollar therapies.
Story Snapshot
- Garvan Institute’s RCT shows metformin reduces daily insulin by 12% in adults with type 1 diabetes without improving insulin resistance.
- World’s first adult randomized trial involved 40 participants over 6 months, confirming stable blood sugar with less insulin burden.
- Off-label use already common in 10-13% of patients; results validate anecdotal benefits with hard evidence.
- Researchers now probe metformin’s mysterious mechanism after disproving initial hypothesis.
- Promises accessible relief from insulin’s mental and physical toll, especially for low-income patients worldwide.
Trial Design and Key Results
Garvan Institute of Medical Research and UNSW Sydney launched the world’s first randomized controlled trial in adults with type 1 diabetes. Forty participants took metformin or placebo for six months. Metformin cut daily insulin requirements by 12% while maintaining stable blood sugar levels. The trial disproved the hypothesis that metformin improves insulin resistance in type 1 diabetes, unlike its role in type 2. Participants reported easier management of their condition.
Dr. Snaith, lead researcher at Garvan, highlighted the practical impact. Patients used significantly less insulin without glycemic changes. This outcome eases the constant calculations and injection fatigue that define type 1 life. A safe, proven drug offers real relief where high-cost insulins dominate.
Metformin’s Long History in Diabetes Care
Metformin originated from French lilac, used medicinally for centuries and commercially for about 100 years. Doctors prescribe it as first-line therapy for type 2 diabetes to curb liver glucose output and boost insulin sensitivity. In type 1 diabetes, an autoimmune condition destroying insulin-producing cells since insulin’s 1921 discovery, off-label use targeted presumed resistance. Up to 13% of Australian type 1 patients, around 13,000 people, already took it anecdotally before this trial.
Type 1 diabetes strikes 8-10% of global diabetics. Lifesaving insulin brings injection hassles, hypoglycemia dangers, and mental strain. Metformin’s $4 monthly cost and safety profile suit resource-poor areas. Prior non-randomized evidence hinted at benefits, but anecdotes lacked rigor until now.
Researchers Driving the Discovery
Dr. Snaith led the trial, stressing insulin burden reduction as a top priority for patients. Professor Jerry Greenfield, co-leader from Garvan and UNSW, noted the unexpected results. Metformin works differently in type 1 than type 2, sparking mechanistic studies. Their academic partnership avoids pharmaceutical sway since metformin is generic and off-patent. Patient advocates and clinicians push for evidence-based off-label options.
Garvan Institute sponsored the study, focusing on diabetes innovation through drug repurposing. This sidesteps billion-dollar new drug development. Diabetes organizations may soon update guidelines based on these principals’ work.
This cheap drug could help people with type 1 diabetes use less insulin https://t.co/KqoLpQ8u3t pharma education pic.twitter.com/irwPKE6PpV
— LifeScienceZone (@LifeScienceZon1) April 16, 2026
Immediate Relief and Future Promise
Short-term, 12% less insulin means fewer injections and lower hypoglycemia risk, lifting daily burdens for millions with type 1. Long-term, guidelines could embrace metformin as adjunct therapy, saving costs against pricey biologics. Low-income communities gain most from this democratization of care. Socially, better adherence improves quality of life; politically, it promotes generic repurposing policies.
The trial challenges insulin-only paradigms in type 1 management. Ongoing research unravels metformin’s puzzle despite its century-long use. No regulatory approvals for type 1 yet, but off-label prescribing persists. Larger trials could confirm scalability.
Sources:
How a cheap, century-old drug can improve life with type 1 diabetes
Common drug found to reduce insulin needs in type 1 diabetes
Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes – PMC
